Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (Nasdaq: TDAC) is a blank-check company that completed its initial public offering in December 2024, with a final prospectus filed on Form 424B4. The SPAC is focused on the healthcare and life sciences sector, with its name reflecting an intent to target businesses engaged in translating scientific research into clinical or commercial applications. As of its IPO date, TDAC is in the search phase, scouting for a merger or acquisition target within its stated sector mandate. For the full sponsor profile, deal timeline, SEC filing history, and real-time status updates on TDAC, sign up for complete access at SpacDesk.